Thanh bên bài viết

PDF
Ngày xuất bản: 28/09/2023
Số lượt xem tóm tắt: 88
Số lượt xem PDF: 58
DOI: https://doi.org/10.56535/jmpm.v48i7.428
Số xuất bản
Tập 48 Số 7 (2023): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 7 - 2023
Chuyên mục
Bài báo
Trích dẫn bài báo
Hồ, V. H., Nghiêm, T. M. C., Cấn, V. M., Ngô, T. H., & Bùi, K. C. (2023). PRE-CLINICAL RESEARCH ON THE APPLICATION OF CAR-T THERAPY IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. Tạp chí Y Dược học Quân sự, 48(7), 133-143. https://doi.org/10.56535/jmpm.v48i7.428

PRE-CLINICAL RESEARCH ON THE APPLICATION OF CAR-T THERAPY IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA

Ho Viet Hoanh1, , Nghiem Thi Minh Chau1, Can Van Mao2, Ngo Thu Hang2, Bui Khac Cuong2
1 Military Hospital 103, Vietnam Military Medical University
2 Vietnam Military Medical University

Nội dung chính của bài viết

Tóm tắt

Objectives: To create chimeric antigen receptor (CAR) T cells and evaluate the effect on CD19+ B cells in animal models of acute lymphoblastic leukemia. Methods: An experimental research (In vitro and In vivo) was conducted at the Department of Pathophysiology, Military Medical University, from June 2019 to 2022. Results: Successfully transformed and created CAR-T cells by nucleofection technology; the survival rate of cells after transformation was 48.9 - 60.7%. The expression of CAR molecules on the T cell surface after 21 and 28 days of culture were 66.23% and 97.34%, respectively. CAR-T cells could proliferate vigorously when co-cultured with cancer cells carrying CD19+, and the ability to lyse cancer cells carrying CD19+ after 6 and 24 hours (lysis efficiency was 24.8 - 71.8%, respectively); this ability increased with the proportion of CAR-T cells present in the medium and with the time of co-culture. CAR-T cell block restricted the proliferation of CD19+ cancer cells (through Luciferase activity), prolonged the survival time, and increased the survival rate of the murine model of acute lymphoblastic leukemia. Conclusion: CAR-T cells can grow when co-cultured with CD19 receptor-expressing cells and CD19+ cancer cell lysis. The excellent effect when using generated CAR-T cells to treat a mouse model of acute leukemia was assessed by Luciferase activity associated with CD19+ cancer cells, survival time, and mouse weight.

Chi tiết bài viết

Từ khóa

CAR-T therapy, Acute lymphoblastic leukemia

Tài liệu tham khảo

1. Alabanza L. et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol. Ther. 2017; 25:2452-2465.
2. Brudno JN and JN Kochenderfer. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018; 15(1):31-46.
3. K Nagle, B Tafuto, L Palladino Kim, and J S Parrott. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis. Med Oncol. 2018; 35(11):144.
4. Kaskova ZM, Tsarkova AS, Yampolsky IV. 1001 lights: Luciferins, luciferases, their mechanisms of action and applications in chemical analysis biology and medicine. Chem Soc Rev. 2016; 45:6048-6077.
5. Lee, DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385(9967):517-528.
6. Olweus, J. Manufacture of CAR-T cells in the body. Nat Biotechnol. 2017; 35(6):520-521.
7. Sommermeyer D, Hill T, Shamah SM, Salter AI, Chen Y, Mohler KM, et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia. 2017; 31(10):2191-2199
8. Sommermeyer, D et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia. 2017; 31:2191-2199.
9. Sophia Stock, Michael Schmitt, Leopold Sellner. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. Int J Mol Sci. 2019; 20(24): 6223. doi: 10.3390/ijms20246223.
10. Ying, Z et al. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. 2019; 25:947-953.